Real-World Analyses of the Treatment Conditions in Patients Initiating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor in Taiwan-Reference-Cited by-同舟云学术

Real-World Analyses of the Treatment Conditions in Patients Initiating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor in Taiwan

Published:2022 Issue: Volume: Page:
ISSN:1340-3478
Container-title:Journal of Atherosclerosis and Thrombosis
language:en
Short-container-title:JAT

Author:

Lin Po-Lin¹,Wu Yen-Wen²,Lin Chao-Feng³,Yeh Hung-I³,Chang Wei-Ting⁴,Charng Min-Ji⁵,Huang Po-Hsun⁶,Lin Chih-Chan⁷,Lin Tsung-Hsien⁸,Lin Wei-Wen⁹,Hsieh I-Chang¹⁰,Kuo Feng-Yu¹¹,Chen Ching-Pei¹²,Li Yi-Heng⁷

Affiliation:

1. Division of Cardiology, Department of Internal Medicine, Hsinchu MacKay Memorial Hospital

2. Division of Cardiology, Cardiovascular Medical Center, Far Eastern Memorial Hospital; Department of Nuclear Medicine, Far Eastern Memorial Hospital; School of Medicine, National Yang Ming Chiao Tung University

3. Cardiovascular Center, Department of Medical Research, MacKay Memorial Hospital and Department of Medicine, Mackay Medical College

4. Institute of Clinical Medicine, College of Medicine, National Cheng Kung University; Division of Cardiology, Department of Internal Medicine, Chi Mei Medical Center; Department of Biotechnology, Southern Taiwan University of Science and Technology

5. Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital; School of Medicine, National Yang Ming Chiao Tung University

6. Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital; Institute of Clinical Medicine and Cardiovascular Research Center, National Yang Ming Chiao Tung University

7. Division of Cardiology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University

8. Division of Cardiology, Department of Internal Medicine, Kaohsiung Medical University Hospital; Department of Internal Medicine, Department of Pharmacology, Faculty of Medicine, College of Medicine, Kaohsiung Medical University

9. Cardiovascular Center, Taichung Veterans General Hospital; Department of Life Science, Tunghai University

10. Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University College of Medicine

11. Division of Cardiology, Department of Medicine, Kaohsiung Veterans General Hospital

12. Division of Cardiology, Department of Internal Medicine, Changhua Christian Hospital

Publisher

Japan Atherosclerosis Society

Subject

Biochemistry (medical),Cardiology and Cardiovascular Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/jat/advpub/0/advpub_63789/_pdf

Reference25 articles.

1. 1) Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PVNA guidelines on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guideline. J Am Coll Cardiol, 2019; 73: e285-350

2. 2) Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidemias: lipid modification to reduce cardiovascular risk. Eur Heart J, 2020; 41: 111-188

3. 3) Chen PS, Lee M, Tang SC, Huang PH, Yeh HI, Hou YJ, Hsieh IC, Lee JT, Jeng JS, Li YH. 2022 focused update of the 2017 Taiwan lipid guidelines for high risk patients: Coronary artery disease, peripheral artery disease and ischemic stroke. J Formos Med Assoc, 2022; 121: 1363-1370

4. 4) Zhang DW, Lagace TA, Garuti R, Zhao Z, McDonald M, Horton JD, Cohen JC, Hobbs HH. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem, 2007; 282: 18602-18612

5. 5) Rosenson RS, Hegele RA, Fazio S, Cannon CP. The evolving future of PCSK9 inhibitors. J Am Coll Cardiol, 2018; 72: 314-329

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association of health information technology-driven multidisciplinary approaches with low-density lipoprotein cholesterol target achievement in patients with an acute coronary syndrome;American Journal of Preventive Cardiology;2024-03

2. Challenges with PCSK9 Inhibitors Use in Asia Given Real-World Data Implications;Journal of Atherosclerosis and Thrombosis;2023-09-01